Pipeline

PIPELINE

NIT is currently conducting multiple clinical trials of NT-I7 as a monotherapy and in combination with leading immunotherapeutics such as checkpoint inhibitors, cancer vaccines, and more.

In addition, NIT is relentlessly conducting proof-of-concept animal studies in additional indications to further strengthen our pipeline and broaden the proof of applicability of NT-I7.

NT-I7 (efineptakin alfa) Development Program

Disease Area Study Indication / Combination Pre-clinical Phase 1 Phase 1/2 Phase 2 Phase 3 Collaborator Link
ONCOLOGY NIT-106 High Risk Skin Cancers / TECENTRIQ 새창으로 열기
NIT-110 Solid Tumors1 / KEYTRUDA (KEYNOTE-A60) 새창으로 열기
GX-I7-CA-006 TNBC / KEYTRUDA (KEYNOTE-899) 2 새창으로 열기
NIT-109 Gastric, GEJ, & EAC / OPDIVO 새창으로 열기
NIT-119 NSCLC (1L) / TECENTRIQ
NIT-112 LBCL / KYMRIAH
NIT-104 GBM (single dose) 새창으로 열기
NIT-107 GBM (multi dose)3 새창으로 열기
NIT-115 SCCHN3,4
IMMUNOLOGY
& INFECTIOUS
DISEASES
NIT-116 COVID-19 새창으로 열기
NIT-118 COVID-19 3 새창으로 열기
NIT-105 Vaccine Adjuvant: Elderly Cancer Survivors 3 새창으로 열기
NIT-113 Progressive Multifocal Leukoencephalopathy 3,5
NIT-114 Idiopathic CD4 Lymphocytopenia 3,6
OTHER N/A Acute Radiation Syndrome
1. TNBC, NSCLC, SCLC, PaC, MSS-CRC
2. Genexine sponsored; NIT co-funds under 3-way agreement with Merck
3. Investigator-initiated trial
4. Squamous Cell Carcinoma of Head and Neck, Window-of-Opportunity
5. Orphan Drug Designation (US Jun 2020)
6. Orphan Drug Designation (EU May 2017 US Apr 2019)